Description: Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Home Page: www.bioventus.com
BVS Technical Analysis
4721 Emperor Boulevard
Durham,
NC
27703
United States
Phone:
919 474 6700
Officers
| Name | Title |
|---|---|
| Mr. Kenneth M. Reali | CEO & Director |
| Mr. Mark Singleton | Sr. VP, CFO & Principal Accounting Officer |
| Mr. Anthony James | VP of Operations and Quality |
| Mr. Miguel O. Beltran-Delgado | Sr. VP of Operations |
| Ms. Alessandraa Pavesio | Sr. VP & Chief Science Officer |
| Mr. David Crawford | VP of Investor Relations & Treasurer |
| Mr. Anthony D'Adamio | Sr. VP, Gen. Counsel & Corp. Sec. |
| Ms. Katrina J. Church | Sr. VP & Chief Compliance Officer |
| Mr. Jeff Welch | VP of Bus. Devel. |
| Mr. Christopher K. Yamamoto | Sr. VP of Corp. Devel. & Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 12.285 |
|---|---|
| Trailing PE: | 14.75 |
| Price-to-Book MRQ: | 0.5841 |
| Price-to-Sales TTM: | 0.3129 |
| IPO Date: | 2021-02-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 1160 |